On the stock market since 2022, it operates in the world of health and science. It has 10,600 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
The company sells $1.1B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 69 buys and 65 sells. Management buying with its own money is usually read as a good sign.
A loss of $4.6M against $1.1B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, EHAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EHAB has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.